US20160376216A1 - Novel anti-neurodegenerative natural compounds isolated from Alpiniae Oxyphyllae Fructus and their total synthesis - Google Patents

Novel anti-neurodegenerative natural compounds isolated from Alpiniae Oxyphyllae Fructus and their total synthesis Download PDF

Info

Publication number
US20160376216A1
US20160376216A1 US15/260,336 US201615260336A US2016376216A1 US 20160376216 A1 US20160376216 A1 US 20160376216A1 US 201615260336 A US201615260336 A US 201615260336A US 2016376216 A1 US2016376216 A1 US 2016376216A1
Authority
US
United States
Prior art keywords
compound
hydroxy
methylphenyl
induced
mptp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/260,336
Inventor
Ming Yuen LEE
Zaijun Zhang
Guohui Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Macau
Original Assignee
University of Macau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Macau filed Critical University of Macau
Priority to US15/260,336 priority Critical patent/US20160376216A1/en
Publication of US20160376216A1 publication Critical patent/US20160376216A1/en
Priority to US15/727,638 priority patent/US10011555B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to novel compounds for treatment of neurodegenerative diseases.
  • the present invention relates to isolated and synthesized compounds, methods of isolating or preparing the compounds, use of the compounds for treating neurodegenerative diseases.
  • Parkinson's disease is the second most common neurodegenerative disease with physiological manifestations including tremors, bradykinesia, abnormal postural reflexes, rigidity and akinesia. It results primarily from the death of dopaminergic (DA) neurons in the substantia nigra.
  • Current therapies for PD mainly provide symptomatic improvement by replacing neurotransmitters or controlling their metabolism to restore their imbalance. Since these therapies are not altering the underlying disease process, they usually have little or no impact on disease progression.
  • the present invention in one aspect, provides a compound with Formula I:
  • R 1 and R 3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxy, alkyloxy, hydroxyl, amino, nitro, alkylthio, acyl, cyano, acylamino, halo and ester; and R 2 and R 4 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, aryl, heteroaryl, alkyoxy, acyl, acylamino and halo.
  • R 1 and R 3 are independently unsubstituted or substituted (C1-C3) alkyl; and R 2 and R 4 are H.
  • the compound with Formula I is an isolated and purified ((R)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid).
  • the compound ((R)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) is represented as the following formula (compound 1).
  • the compound with Formula I is ((S)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) or (4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid).
  • the compounds ((S)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) (compound 4) and (4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) (compound 5) are represented as the below formulae, respectively.
  • the present invention provides a composition comprising the compound with Formula I and a pharmaceutically acceptable salt or carrier.
  • Another aspect of the present invention provides use of the compound with Formula I for protection against neural damage.
  • Another aspect of the present invention provides use of the compound with Formula I for treatment of neurodegenerative disease.
  • the neurodegenerative disease is Parkinson's disease.
  • Another aspect of the present invention provides a method of treating Parkinson's disease, or protecting against neural damage or neural cells loss, comprising the step of administering the compound with Formula I to a subject in need.
  • Another aspect of the present invention provides a method of treating neurodegenerative disease in a human patient comprising administrating to the patient a therapeutically effective amount of the compound with Formula I and chrysin, wherein the compound exhibits a synergistic effect with chrysin for neuroprotective effect.
  • Another aspect of the present invention provides a compound with Formula II:
  • R 1 and R 3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, alkenly, alkynyl, aryl, heteroaryl, carboxy, alkyloxy, hydroxyl, amino, nitro, alkylthio, acyl, cyano, acylamino, halo and ester; and R 2 and R 4 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloakly, aryl, heteroaryl, alkyoxy, acyl, acylamino and halo.
  • R 1 and R 3 are in independently unsubstituted or substituted (C1-C3) alkenyl; and R 2 and R 4 are H.
  • the compound with Formula II is an isolated and purified ((4S)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid) or ((4R)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid).
  • compositions comprising the compound with Formula II and a pharmaceutically acceptable salt or carrier.
  • Another aspect of the present invention provides use of the compound with Formula II for protection against neural damage.
  • Another aspect of the present invention provides use of the compound with Formula II for treatment of neurodegenerative disease.
  • the neurodegenerative disease is Parkinson's disease.
  • Another aspect of the present invention provides a method of treating Parkinson's disease, or protecting against neural damage or neural cells loss, comprising the step of administering the compound with Formula II to a subject in need.
  • Another aspect of the present invention provides a method for preparing an isolated and purified compound from A. oxyphyllae fructus, comprising the steps of:
  • step (f) further comprises
  • step (f) further comprises purifying the first bioactive fraction of step (e) by preparative high performance liquid chromatography with isocratic solution to obtain the compound ((4S)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid) and the compound ((4R)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid).
  • FIG. 1 shows the neuroprotective effects of compounds 1-5 on MPP + -induced primary CGNs damage. *p ⁇ 0.05 compared with MPP + treatment alone group.
  • FIGS. 2A and 2B show the effects of compound 1 on 6-OHDA-induced PC12 cells damage. ##p ⁇ 0.01 versus control group; **p ⁇ 0.01 versus vehicle group.
  • FIGS. 3A-3G show the effects of compound 1 on protecting zebrafish from MPTP-induced dopaminergic neuron loss. ##p ⁇ 0.01 versus control group; *p ⁇ 0.01 versus vehicle group; **p ⁇ 0.01 versus vehicle group.
  • FIGS. 4A and 4B show compound 1 reversed decrease of total distance traveled induced by MPTP in the zebrafish. ##p ⁇ 0.01 versus control group (without MPTP treatment); *p ⁇ 0.05 versus MPTP-treated group.
  • FIG. 5 shows the synergistic neuroprotective effects of compound 1 and chrysin on MPP + -induced primary CGNs damage. *p ⁇ 0.05 compared with MPP + treatment alone group; #p ⁇ 0.05 compared with 3 ⁇ M chrysin plus MPP + treatment group; $p ⁇ 0.05 compared with 6 ⁇ M chrysin plus MPP + treatment group.
  • FIG. 6 shows workflow of drug treatments and behavioral testing.
  • FIGS. 7A-7D show compound 1 ameliorated the movement impairment of MPTP-injected mice.
  • A Pole test;
  • B Duration of foot printing test;
  • C Rotarod test;
  • FIGS. 8A-8C show compound 1 protected TH-positive dopaminergic neuron loss in the MPTP-injected mice.
  • A TH immunostaining of representative midbrain sections from rostral to caudal.
  • Fractions A-M normal-phase silica gel column chromatography with chloroform mixed with increasing amount of methanol from 0% to 20% to yield 13 fractions (Fractions A-M). Bioassay showed that fraction G is the most bioactive.
  • Fraction G was fractionated by silica gel column chromatography eluting chloroform mixed with increasing amount of methanol from 0% to 2% to yield five major sub-fractions GS1, GS2, GS3, GS4 and GS5.
  • Sub-fraction GS2 was further fractionated by sephadex LH-20 and compound 1 was obtained from an elution using 100% methanol. The purity of compound 1 was monitored by thin layer chromatography with iodine as indicator.
  • the most active fraction G was fractionated by preparative high performance liquid chromatography and compounds 2 and 3 were obtained by an elution with 25% acetonitrile. The purity of compounds 2 and 3 was monitored by UV at 254 nm
  • the present invention provides evidences to support the use of compounds 1, 2 and 3 as reference chemical markers for controlling the quality of A. oxyphyllae fructus.
  • H 2 O 2 (32.0 g, 282 mmol, 1.5 eq, 30% in H 2 O) was added dropwise to a suspension of compound g (43.5 , 188 mol, 1.0 eq) and K 2 CO 3 (10.4 g, 75.2 mmol, 0.4 eq) in DMSO (220 mL) at room temperature, the solution was then stirred at room temperature for 3 hrs. Additional H 2 O 2 (32.0 g, 282 mmol, 1.5 eq, 30% in H 2 O) was added dropwise at room temperature for 1 hr.
  • HBr (235 mL, 33% in AcOH) solution was added to a solution of compound i (47.1 g, 188 mmol) in AcOH (235 mL) dropwise at room temperature, then refluxed overnight.
  • the mixture was diluted with EtOAc and H 2 O.
  • the organic layer was washed with H 2 O and saturated aqueous NaCl, and subsequently concentrated.
  • the residue was diluted with EtOH (400 ml) and H 2 O (40 mL) with LiOH.H 2 O (31.6 g, 752 mmol) added; the mixture was stirred for 1.5 hours at room temperature and then concentrated.
  • the residue was diluted, and acidified with 1N HCl to pH 2 ⁇ 3.
  • N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is the precursor of 1-methyl-4-phenylpyridinium (MPP + ), a mitochondrial electron-transport chain (ETC) complex I inhibitor generated from MPTP by the dopaminergic catabolic enzyme monoamine oxidase B.
  • ETC mitochondrial electron-transport chain
  • MPP + 1-methyl-4-phenylpyridinium
  • ETC mitochondrial electron-transport chain
  • CGNs Primary cerebellar granule neurons
  • FIG. 1 shows that compounds 1-5 prevented MPP + -induced CGNs damage.
  • Compound 1 shows neuroprotective effect on MPP + -induced primary SD rat CGNs damage in a dose-dependent manner with E max at the concentration of 50 ⁇ M.
  • Compound 2 has neuroprotective effect on MPP + -induced primary SD rat CGNs damage with E max at the concentration of 50 ⁇ M.
  • Compound 3 has neuroprotective effect on MPP + -induced primary SD rat CGNs damage with E max at the concentration of 25 ⁇ M.
  • Compound 4 has neuroprotective effect on MPP + -induced primary SD rat CGNs damage with E max at the concentration of 12 ⁇ M.
  • Compound 5 has neuroprotective effect on MPP + -induced primary SD rat CGNs damage in a dose-dependent manner with E max at the concentration of 50 ⁇ M.
  • FIG. 1 shows that compounds 1-5 can protect against neural damage induced by MPP + , and be used to treat neurodegenerative diseases.
  • PC12 Rat pheochromocytoma cells
  • 6-OHDA was cytotoxic to PC12 cells but compound 1 could alleviate the cytotoxic effect in a dose-dependent manner as shown in FIG. 2B .
  • Compound 1 exhibited a significant and maximum neuroprotective effect to 6-OHDA treated PC12 at 50 ⁇ M.
  • Baicalein one of the main flavonoids extracted from the root of Scutellaria baicalensis Georgi (SBG), has been demonstrated to prevent against neuronal damage induced by 6-OHDA or MPTP in both in vitro and in vivo models of Parkinson's disease (Im, Joo et al. 2005; Lee, Noh et al. 2005; Cheng, He et al. 2008; Mu, He et al. 2009; Mu, He et al. 2011).
  • baicalein was used as a positive control, which at the concentration of 100 ⁇ M obviously protected PC12 cells against 6-OHDA-induced neuronal damage.
  • FIGS. 2A and 2B show that compound 1 can have neroprotective effect to 6-OHDA treated PC12. Further, compound 1 has neuroprotective effect on 6-OHDA-induced PC12 cell damage in a dose-dependent manner with maximum efficacy (Emax)at the concentration of 50 ⁇ M.
  • Emax maximum efficacy
  • the 3 dpf zebrafish larvae were co-treated with 200 ⁇ M MPTP and various concentrations of compound 1 for 4 days.
  • the total distance the larvae traveled was recorded using a 96-well plate (with 1 fish/well and 12 larvae per group) filled with 200 ⁇ l embryo medium. Larvae were allowed to accommodate in the system for an hour before data acquisition.
  • the swimming pattern of each larva was recorded for 10 min in 3 times, with each record session separated by 10 min.
  • the total distance traveled was estimated as the distance (in mm) that the larva had moved during one session (10 min).
  • compound 1 attenuated MPTP-induced reduction of total distance traveled of the larvae in a dose dependent manner.
  • CGNs Primary cerebellar granule neurons
  • both compound 1 and chrysin protected MPP + -induced cell damage in CGNs in a dose-dependent manner.
  • the cell viability was significantly enhanced when the cells were treated with 25 and 50 ⁇ M of compound 1 as well as with 12 and 25 ⁇ M of chrysin as compared with the control group treated with MPP + alone (p ⁇ 0.05).
  • CGNs were also co-treated with compound 1 and chrysin to explore the pharmacological interaction between two compounds. It is found that at higher concentrations such as 25 and 50 ⁇ M, the co-treatment did not exert any neuro-protective effect but imposed toxicity on the CGNs (data not shown).
  • compound 1 and chrysin showed significant synergistic neuroprotective effect as compared with cells treated with MPP + alone, MPP + /compound 1 and MPP + /chrysin.
  • mice Eight-10 weeks of age, 18-22 g were used in this study. The animals were maintained in 12/12 h light/dark cycle and allowed access to food and water ad libitum. They were allowed to acclimate for 7 days before treatment. As shown in FIG. 6 , all the animals were conducted behavioral training (pole climbing, rotarod running and foot printing) for total 4 days before MPTP injection. Then the mice were injected intraperitioneally (i.p.) with 20 mg/kg MPTP hydrochloride (Sigma Aldrich, St. Louis, Mo.), at 2 h internal for total 4 injections. Normal control group were received saline (0.1 mL/10 g) by i.p.
  • compound 1 (5, 10 and 20 mg/kg), rasagiline (1 mg/kg) and equal volume of vehicle (olive oil, 0.1 mL/10 g) were administrated by i.g. Then, compound 1, rasagiline or vehicle was given by i.g. once per day for total 7 days (day 1-7). Each of six groups was comprised of 10 mice.
  • mice were observed for neurobehavoral changes by pole test, rotarod test and footprint test. All the tests were done between 9 am and 2 pm under normal animal room lighting.
  • the pole test was performed to detect impairment of limb movement.
  • a table tennis ball (5 cm diameter) was equipped on the top of a vertical pole (55 cm length and 1 cm diameter).
  • the pole was wrapped with a double layer of gauze to avoid slipping.
  • the animal was placed head upward on the table tennis ball. The time the animal took to climb down to the floor was used to indicate performance. Three-time repeated testes were carried out for each animal and the mean values were used for statistical analysis.
  • the rotarod test could reveal motor coordination ability.
  • a Rotarod system (YLS-4C, Academy of Medical Sciences of Shandongzhou, China) was set at an accelerating program with a starting speed of 5 rpm to a final speed of 40 rpm. Mice were allowed to adjust their posture in order to maintain their balance on a rotating rod during speed accelerating. Infrared beams are used to detect with a mouse has fallen onto the base grid beneath the rotarod. The system logs the fall as the end of the experiment for that mouse, and the total time on the rotarod was recorded. For testing, 5 mice were tested at the same time. The average retention time on the rod was calculated.
  • mice with their forepaws and hind paws colored with red ink were trained to walk through a 5 cm-wide, 100-cm-long corridor. Their footsteps were recorded on a white absorbing paper.
  • mice were sacrificed for tissue preparation on the day 9 as described in FIG. 6 .
  • Mice in each group were anesthetized and perfused intracardially with 0.9% sodium chloride containing heparin, and then fixed with 4% paraformaldehyde (PFA).
  • PFA paraformaldehyde
  • Each brain was removed, dehydrated with graded alcohol and embedded in paraffin wax, coronally sectioned for 5 ⁇ M. The rostral and caudal part of the brain was divided for immunohistochemistry of substantia nigra pars compacta (SNpc).
  • Sections were then incubated for 1 h at room temperature with a rabbit anti-mouse TH polycolonal antibody (1:1000; Millipore, USA) diluted in Immunol Staining Primary Antibody Dilution Buffer. Then the sections were incubated with a biotinylated HRP-conjugated secondary antibody for 30 min at room temperature. TH-positive neurons were then visualized using a DAB Kit according to the manufacturer's instructions (Shanghai, Gene Company, China). The peroxidase reaction was stopped after 3 min Finally, sections were cover slipped with neutral balsam. The results were analyzed by counting the numbers of TH-positive cells at ⁇ 10 magnifications on a stereomicroscope (BX51, Olympus Corp. Japan). TH-positive cells in 8 position-matched sections of each mouse were counted manually by operator who was blinded to the drug treatment. The average number of TH-positive cells per section was used to represent dopaminergic neuron livability.
  • FIGS. 7A to 7D show that MPTP significantly increased the time climbing down from the pole ( FIG. 7A ), delayed the time of crossing the corridor ( FIG. 7B ), reduced the time of mice on rotating rotor rod ( FIG. 7C ) and caused mice to lose their normal gait, shortening stride length ( FIG. 7D ). As such, FIGS. 7A to 7D show that compound 1 treatment largely corrected the movement abnormalities in a dose-dependent manner.
  • the present invention provides three isolated and purified compounds: 1 ((R)-4-(2-hydroxy-5-methylphenyl)-5-mehtylhexanoic acid), 2 ((4S)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid) and 3 ((4R)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid), isolated form A.
  • oxyphyllae fructus with neuroprotective effect as shown in the above examples; and two synthesized compounds: 4 ((S)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) and 5 (4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) with neuroprotective effect.
  • These five lead compounds have neuroprotective effects which could be developed into therapeutic agent for neurodegenerative diseases (e.g. Parkinson's disease).
  • the present invention provides a simple and easy method for extraction and purification of these three novel compounds 1-3 from A. oxyphyllae fructus and an elaborated procedure for synthesizing compounds 1, 4 and 5.
  • In vitro neuroprotective activity on CGNs of compounds 1-5 is also presented. Furthermore, this invention shows that compound 1 possesses in vivo and in vitro neuroprotective activities on PC12 cells and zebrafish.
  • Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol 49(1):271-280.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

This invention is directed to novel compounds isolated or derived from Alpiniae oxyphyllae fructus, chemically synthesized novel compounds, methods of preparing the novel compounds and uses thereof as neuroprotectants or drugs for treating neurodegenerative diseases such as Parkinson's disease.

Description

    CROSS-REFERENCE TO RELATED APPLICATION
  • This application claims benefit under 35 U.S.C. §199(e) of U.S. Provisional Application having Ser. No. 61/782,870 filed Mar. 14, 2013, which is hereby incorporated by reference herein in its entirety.
    • FIELD OF INVENTION
  • The present invention relates to novel compounds for treatment of neurodegenerative diseases. In particular, the present invention relates to isolated and synthesized compounds, methods of isolating or preparing the compounds, use of the compounds for treating neurodegenerative diseases.
    • BACKGROUND OF INVENTION
  • Neurodegenerative disease is directed to a range of conditions which primarily affect the neurons in the human brain. Parkinson's disease (PD) is the second most common neurodegenerative disease with physiological manifestations including tremors, bradykinesia, abnormal postural reflexes, rigidity and akinesia. It results primarily from the death of dopaminergic (DA) neurons in the substantia nigra. Current therapies for PD mainly provide symptomatic improvement by replacing neurotransmitters or controlling their metabolism to restore their imbalance. Since these therapies are not altering the underlying disease process, they usually have little or no impact on disease progression.
    • SUMMARY OF INVENTION
  • It is therefore an object of the present invention to provide novel compounds for the treatment of neurodegenerative diseases, methods of preparing the compounds, their compositions and uses thereof.
  • Accordingly, the present invention, in one aspect, provides a compound with Formula I:
  • Figure US20160376216A1-20161229-C00001
  • wherein R1 and R3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxy, alkyloxy, hydroxyl, amino, nitro, alkylthio, acyl, cyano, acylamino, halo and ester; and R2 and R4 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, aryl, heteroaryl, alkyoxy, acyl, acylamino and halo.
  • In an exemplary embodiment, for the compound with Formula I, R1 and R3 are independently unsubstituted or substituted (C1-C3) alkyl; and R2 and R4 are H.
  • In another exemplary embodiment, the compound with Formula I is an isolated and purified ((R)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid). The compound ((R)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) is represented as the following formula (compound 1).
  • Figure US20160376216A1-20161229-C00002
  • In a further exemplary embodiment, the compound with Formula I is ((S)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) or (4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid). The compounds ((S)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) (compound 4) and (4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) (compound 5) are represented as the below formulae, respectively.
  • Figure US20160376216A1-20161229-C00003
  • It yet another aspect, the present invention provides a composition comprising the compound with Formula I and a pharmaceutically acceptable salt or carrier.
  • Another aspect of the present invention provides use of the compound with Formula I for protection against neural damage.
  • Another aspect of the present invention provides use of the compound with Formula I for treatment of neurodegenerative disease.
  • In an exemplary embodiment, the neurodegenerative disease is Parkinson's disease.
  • Another aspect of the present invention provides a method of treating Parkinson's disease, or protecting against neural damage or neural cells loss, comprising the step of administering the compound with Formula I to a subject in need.
  • Another aspect of the present invention provides a method of treating neurodegenerative disease in a human patient comprising administrating to the patient a therapeutically effective amount of the compound with Formula I and chrysin, wherein the compound exhibits a synergistic effect with chrysin for neuroprotective effect.
  • Another aspect of the present invention provides a compound with Formula II:
  • Figure US20160376216A1-20161229-C00004
  • wherein R1 and R3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, alkenly, alkynyl, aryl, heteroaryl, carboxy, alkyloxy, hydroxyl, amino, nitro, alkylthio, acyl, cyano, acylamino, halo and ester; and R2 and R4 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloakly, aryl, heteroaryl, alkyoxy, acyl, acylamino and halo.
  • In an exemplary embodiment, for the compound with Formula II, R1 and R3 are in independently unsubstituted or substituted (C1-C3) alkenyl; and R2 and R4 are H.
  • In a further exemplary embodiment, the compound with Formula II is an isolated and purified ((4S)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid) or ((4R)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid). The compounds ((4S)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid) (compound 2) and ((4R)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid) (compound 3) are represented as the following formulae, respectively.
  • Figure US20160376216A1-20161229-C00005
  • Another aspect of the present invention provides a composition comprising the compound with Formula II and a pharmaceutically acceptable salt or carrier.
  • Another aspect of the present invention provides use of the compound with Formula II for protection against neural damage.
  • Another aspect of the present invention provides use of the compound with Formula II for treatment of neurodegenerative disease.
  • In an exemplary embodiment, the neurodegenerative disease is Parkinson's disease.
  • Another aspect of the present invention provides a method of treating Parkinson's disease, or protecting against neural damage or neural cells loss, comprising the step of administering the compound with Formula II to a subject in need.
  • Another aspect of the present invention provides a method for preparing an isolated and purified compound from A. oxyphyllae fructus, comprising the steps of:
      • a) extracting samples of A. oxyphyllae fructus with aqueous alcohol solution under low pressure hot reflux and removing the solvent to obtain a crude extract;
      • b) reconstituting the crude extract in step (a) with ethanol to obtain ethanol extract solution;
      • c) absorbing the ethanol extract solution into silica gel and removing ethanol to obtain silica gel extract;
      • d) extracting the silica gel extract with organic solvents successively under normal pressure hot reflux to obtain bioactive parts;
      • e) fractionating the bioactive parts and eluting with solvent mixture with increasing polarity to obtain a first bioactive fraction
      • f) purifying the first bioactive fraction of step (e) to obtain the compound;
      • wherein the compound is selected from the group consisting of ((R)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid), ((4S)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid) and ((4R)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid).
  • In an exemplary embodiment the step (f) further comprises
      • g) fractioning the first bioactive fraction of step (e) and eluting with solvent mixture with increasing polarity to obtain a second bioactive portion
      • h) purifying the second bioactive portion with isocratic elution to obtain the compound ((R)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid).
  • In an exemplary embodiment, the step (f) further comprises purifying the first bioactive fraction of step (e) by preparative high performance liquid chromatography with isocratic solution to obtain the compound ((4S)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid) and the compound ((4R)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid).
    • BRIEF DESCRIPTION OF FIGURES
  • FIG. 1 shows the neuroprotective effects of compounds 1-5 on MPP+-induced primary CGNs damage. *p<0.05 compared with MPP+ treatment alone group.
  • FIGS. 2A and 2B show the effects of compound 1 on 6-OHDA-induced PC12 cells damage. ##p<0.01 versus control group; **p<0.01 versus vehicle group.
  • FIGS. 3A-3G show the effects of compound 1 on protecting zebrafish from MPTP-induced dopaminergic neuron loss. ##p<0.01 versus control group; *p<0.01 versus vehicle group; **p<0.01 versus vehicle group.
  • FIGS. 4A and 4B show compound 1 reversed decrease of total distance traveled induced by MPTP in the zebrafish. ##p<0.01 versus control group (without MPTP treatment); *p<0.05 versus MPTP-treated group.
  • FIG. 5 shows the synergistic neuroprotective effects of compound 1 and chrysin on MPP+-induced primary CGNs damage. *p<0.05 compared with MPP+ treatment alone group; #p<0.05 compared with 3 μM chrysin plus MPP+ treatment group; $p<0.05 compared with 6 μM chrysin plus MPP+ treatment group.
  • FIG. 6 shows workflow of drug treatments and behavioral testing.
  • FIGS. 7A-7D show compound 1 ameliorated the movement impairment of MPTP-injected mice. (A) Pole test; (B) Duration of foot printing test; (C) Rotarod test; (D) Stride length of foot printing test. Results were presented as mean±S.E.M (n=8) of three repeated tests. #p<0.05 and ###p<0.001 compared with control (Ctrl) group; *p<0.05, **p<0.01 and ***p<0.001 compared with vehicle (Veh) treatment group, Rasa, rasagiline.
  • FIGS. 8A-8C show compound 1 protected TH-positive dopaminergic neuron loss in the MPTP-injected mice. (A) TH immunostaining of representative midbrain sections from rostral to caudal. (B) The graph showed TH-positive cell counts±S.E.M (n=8) for the 8 matched adjacent sections. (C) Statistic analysis of average of the data of sections for different treatment groups. Results were presented as mean±S.E.M (n=8). #p<0.05 compared with control (Ctrl) group; *p<0.05 compared with vehicle (Veh) treatment group. Rasa, rasagiline.
    •  DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • As used herein and in the claims, “comprising” means including the following elements but not excluding others.
  • The following examples are given by way of illustration of the present invention but should not be considered to limit the scope of the invention. Reasonable variations, such as those understood by reasonable artisans, can be made without departing from the scope of the present invention.
    • Example 1 Physical-Chemical properties of Compounds 1-5 1. Physical-Chemical Properties of Compound 1
  • ((R)-4-(2-hydroxy-5-methylphenyl)-5-mehtylhexanoic acid)
    • Formula:
  • Figure US20160376216A1-20161229-C00006
  • Physical description: White powder
  • Specific rotation: [α]D 26.2=−11.3 (c 3.0, MeOH), [α]D 250=−19.4 (c 0.72, CH2Cl2).
  • UV (methanol) λ max: 222 nm, 282 nm
  • 1H NMR spectrum (600 MHz, CDCl3, δTMS=0.00 ppm): δ (ppm) 2.18, 2.11 (2H, m, H-2α, 2β), 1.80, 2.17 (2H, m, H-3α, 3β), 2.67 (1H, m, H-4), 1.85 (1H, m, H-5), 1.01 (3H, d, J=6.58 Hz, h-6), 0.74 (3H, d, j=6.65 Hz, H-7), 6.66 (1H, d, J=8.52 Hz, H-3′), 6.85 (1H, d, J=8.52 Hz, H-4′), 6.85 (1H, s, H-6′), 2.27 (3H, s, H-7′)
  • 13C NMR spectrum (125 MHz, CDCl3, δTMS=0.00 ppm): δ (ppm) 178.2 (C-1), 31.7 (C-2), 27.6 (C-3), 44.1 (C-4), 32.7 (C-5), 20.8 (C-6), 21.1 (C-7), 130.1 (C-1′), 151.9 (C-2′), 115.4 (C-3′), 127.4 (C-4′), 129.5 (C-5′), 128.2 (C-6′), 20.6 (C-7′)
  • Mass spectrum (HR-ESI-MS): m/z 235.1369 [M−H]− (calcd for C14H19O3, 235.1339)
    • 2. Physical-Chemical Properties of Compound 2
  • ((4S)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid)
    • Formula:
  • Figure US20160376216A1-20161229-C00007
  • Physical description: yellow oil
  • Specific rotation: [α]D 26.2=−22.5 (c 3.0, MeOH)
  • UV (methanol) λ max: 238 nm
  • 1H NMR spectrum (600 MHz, CDCl3, δTMS=0.00 ppm): δ (ppm) 2.18, 2.16 (2H, m, H-2), 1.97, 1.74 (2H, m, H-3α, 3β), 2.25 (1H, m, H-4), 1.79 (1H, m, H-5), 0.76 (3H, d, J=6.68 Hz, H-6), 0.89 (3H, d, J=6.65 Hz, H-7), 6.40 (1H, s, H-2′), 2.65, 2.64 (2H, m, H-4′α, 4′β), 2.09 (2H, m, H-5′), 1.45 (3H, s, H-7′)
  • 13C NMR spectrum (125 MHz, CDCl3, δTMS=0.00 ppm): δ (ppm) 178.3 (C-1), 45.5 (C-2), 25.6 (C-3), 45.3 (C-4), 31.2 (C-5), 20.4 (C-6), 21.0 (C-7), 139.0 (C-1′), 150.6 (C-2′), 69.0 (C-3′), 35.4 (C-4′), 37.1 (C-5′), 198.6 (C-6′), 27.6 (C-7′)
  • Mass spectrum (HR-ESI-NS): m/z 253.1468 [M−H]− (calcd for C14H21O4, 253.1445)
    • 3. Physical-Chemical Properties of Compound 3
  • ((4R)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5methylhexanoic acid)
    • Formula:
  • Figure US20160376216A1-20161229-C00008
  • Physical description: yellow oil
  • Specific rotation [α]D 262.2=−31.5 (c 3.0, MeOH)
  • UV (methanol) λ max: 238 nm
  • 1H NMR spectrum (600 MHz, CDCl3, δTMS=0.00 ppm): δ (ppm) 2.16 (2H, m, H-2), 1.95, 1.65 (2H, m, H-3α, 3β), 2.53 (1H, m, H-4), 1.79 (1H, m, H-5), 0.77 (3H, d, j=6.68 Hz, H-6), 0.86 (3H, d, J=6.65 Hz, H-7), 6.44 (1H, s, H-2′), 2.66, 2.44 (2H, m, H-4′α, 4β), 2.10 (2H, m, H-5′), 1.46 (3H, s, H-7′)
  • 13C NMR spectrum (125 MHz, CDCl3, δTMS=0.00 ppm): δ (ppm) 178.2 (C-1), 32.1 (C-2), 25.7 (C-3), 42.1 (C-4), 31.9 (C-5), 20.4 (C-6), 20.4 (C-7), 139.1 (C-1′), 149.6 (C-2′), 69.1 (C-3′), 37.0 (C-4′), 35.2 (C-5′), 198.7 (C-6′), 27.5 (C-7′)
  • Mass spectrum (HR-ESI-MS): m/z 253.1480 [M−H]− (calcd for C14H21O4, 253.1445)
  • 4. Physical-Chemical properties of Compound 4
    ((S)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid)
    • Formula:
  • Figure US20160376216A1-20161229-C00009
  • Physical Description: White Powder
  • Specific rotation: [α]D 25.0=+20.0 (c, 0.72, CH2Cl2)
  • 1H NMR spectrum (600 MHz, CDCl3, δTMS=0.00 ppm): δ (ppm) 2.20, 2.13 (2H, m, H-2β, 2β), 1.81, 2.18 (2H, m, H-3α, 3β), 2.67 (1H, m, H-4), 1.86 (1H, m, H-5), 1.02 (3H, d, J=6.5 Hz, H-6), 0.74 (3H, d, J=6.5 Hz, H-7), 6.65 (1H, d, J=8.5 Hz, H-3′), 6.84 (2H, d, J=8.5 Hz, H-4′), 6.84 (1H, s, H-6′), 2.24 (3H, s, H-7′)
  • 13C NMR spectrum (125 MHz, CDCl3, δTMS=0.00 ppm): δ (ppm) 180.2 (C-1), 32.2 (C-2), 27.6 (C-3), 44.3 (C-4), 32.9 (C-5), 20.9 (C-6), 21.3 (C-7), 130.1 (C-1′), 151.8 (C-2′), 115.6 (C-3′), 127.4 (C-4′), 129.4 (C-5′), 128.6 (C-6′), 20.8 (C-7′)
  • Mass spectrum (HR-ESI-MS): m/z 235.1358 [M−H]− (calcd for C14H19O3, 235.1339)
    • 5. Physical-Chemical Properties of Compound 5
  • (4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid)
    • Formula:
  • Figure US20160376216A1-20161229-C00010
  • Physical description: White powder
  • 1H NMR spectrum (600 MHz, CDCl3, δTMS=0.00 ppm): δ (ppm) 2.20, 2.13 (2H, m, H-2α, 2β), 1.82, 2.18 (2H, m, H-3α, 3β), 2.66 (1H, m, H-4), 1.87 (1H, m, H-5), 1.02 (3H, d, J=6.5 Hz, H-6), 0.74 (3H, d, J=6.5 Hz, H-7), 6.65 (1H, d, J=8.5 Hz, H-3′), 6.85 (1H, d, j=8.5 Hz, H-4′), 6.85 (1H, s, H-6′), 2.24 (3H, s, H-7′)
  • 13C NMR spectrum (125 MHz, CDCl3, δTMS=0.00 ppm): δ (ppm) 180.2 (C-1), 32.2 (C-2), 27.6 (C-3), 44.3 (C-4), 32.9 (C-5), 20.7 (C-6), 21.3 (C-7), 130.1 (C-1′), 151.8 (C-2′), 115.6 (C-3′), 127.4 (C-4′), 129.4 (C-5′), 128.6 (C-6′), 20.9 (C-7′)
    • Example 2 Method of Isolating Compound 1 from A. Oxyphyllae Fructus
  • After coarsely pulverized, air-dried fruits of A. oxyphyllae fructus were extracted with 95% aqueous alcohol solution under reflux for three times, the extract solution was dried by rotary evaporator in a water bath. The dried crude extracts of A. oxyphyllae fructus were then suspended in ethanol and absorbed into the silica gel. After removal of ethanol, the dried silica gel was successively extracted with petroleum ether, ethyl acetate and ethanol to yield petroleum ether part, ethyl acetate part and ethanol part respectively. bioassay showed that the ethyl acetate part is the most bioactive and thus selected for further analysis. The ethyl acetate part was subjected for further separated by normal-phase silica gel column chromatography with chloroform mixed with increasing amount of methanol from 0% to 20% to yield 13 fractions (Fractions A-M). Bioassay showed that fraction G is the most bioactive. Fraction G was fractionated by silica gel column chromatography eluting chloroform mixed with increasing amount of methanol from 0% to 2% to yield five major sub-fractions GS1, GS2, GS3, GS4 and GS5. Sub-fraction GS2 was further fractionated by sephadex LH-20 and compound 1 was obtained from an elution using 100% methanol. The purity of compound 1 was monitored by thin layer chromatography with iodine as indicator.
    • Example 3 Method of isolating Compounds 2 and 3 from A. oxyphyllae fructus
  • As presented in example 2, the most active fraction G was fractionated by preparative high performance liquid chromatography and compounds 2 and 3 were obtained by an elution with 25% acetonitrile. The purity of compounds 2 and 3 was monitored by UV at 254 nm
  • The present invention provides evidences to support the use of compounds 1, 2 and 3 as reference chemical markers for controlling the quality of A. oxyphyllae fructus.
    • Example 4 Method of Synthesizing Compounds 1, 4, and 5
  • Compound 1 together with its chiral isomer compound 4 and racemic compound 5 were synthesized as scheme (I) shows:
  • Figure US20160376216A1-20161229-C00011
    Figure US20160376216A1-20161229-C00012
    • 1) Synthesis of 1-(2-methoxy-5-methylphenyl)-2-methypropan-1-one (b)
  • Compound a, 4-Methylanisole, (76.4 g, 625 mmol, 1.0 eq) was added in drops to a solution of AlCl3 (100 g, 750 mmol, 1.2 eq) in DCM (1000 mL) at 0° C., then isoburyryl chloride (80.0 g, 750 mmol, 1.2 eq) was added dropwise to the solution while keeping temperature below 5° C. The mixture was stirred at room temperature for overnight. The mixture was then poured into crush ice (2.0 kg); the organic layer was washed by with H2O and saturated aqueous NaCl, dried over Na2SO4, filtered, and finally dried to give compound b (110 g, 92%) as brown oil.
  • 1H NMR (400 MHz, CDCl3): δ 1.14 (d, J=6.8 Hz, 6H), 2.05 (s, 3H), 3.44-3.51 (m, 1H), 3.85 (s, 3H), 6.85 (d, J=8.4 Hz, 1H), 7.22 (d, J=8.4 Hz, 1H), 7.31 (s, 1H).
    • 2) Synthesis of ethyl-(2E)-3-(2-methyloxy-5-methylphenyl)-4-methypent-2-enoate (c)
  • To a suspension of NaH (34.3 g, 858 mmol, 1.5 eq, 60% in mineral oil) in THF (1000 mL) triethylphosphonoacetate (192 g, 858 mmol, 1.5 eq) was added dropwise while keeping temperature below 10° C. for 40 mins, the solution was then stirred at 0° C. for 30 mins. Compound b (110 g, 572 mmol, 1.0 eq) was added drop by drop while keeping temperature below 10° C. for 20 mins. The mixture was refluxed overnight. The reaction was quenched by aqueous NH4Cl, the organic layer obtained was washed by with H2O and saturated aqueous NaCl; dried over Na2SO4, filtered, and evaporated, the residue was purified by column chromatography on silica gel (PE/EtOAc=100/1˜30/1) to give crude compound c (150 g) as a colorless oil, which contained compound b and compound c.
  • 1H NMR (400 MHz, CDCl3): δ 0.81-1.18 (m, 9H), 2.20 (s, 3H), 2.53-2.59 (m, 1H), 3.67 (s, 3H), 3.89 (q, J=7.2 Hz, 2H), 5.83 (s, 1H), 6.67 (s, 1H), 6.71 (d, J=8.4 Hz, 1H), 6.98 (d, J=8.4 Hz, 1H).
    • 3) Synthesis of ethyl 3-(2-methyloxy-5-methylphenyl)-4-mehtypentanoate (d)
  • A mixture of compound c (150 g, crude) and Pd/C (15 g, 10%) in EtOH (500 mL) was stirred overnight at room temperature under H2 atmosphere and then filtered. The filtrate was evaporated to give crude compound d (100 g, 61% yield for 2 steps) as a colorless oil, which contained compound d (84%, w/w) and compound b (16%, w/w).
  • 1H NMR (400 MHz, CDCl3): δ 0.76 (d, J=6.8 Hz, 3H), 0.79 (d, J=6.8 Hz, 3H) 1.06 (t, J=7.2 Hz, 3H), 1.9201.97 (m, 1H), 2.25 (s, 3H), 2.61-2.75 (m, 2H), 3.223.28 (m, 1H), 3.77 (s, 3H), 3.95 ( q, J=7.2 Hz, 2H), 6.72 (d, J=8.4 Hz, 1H), 6.88 (s, 1H), 6.94 (d, J=8.4 Hz, 1H).
    • 4) Synthesis of 3-(2-methyloxy-5-methylphenyl)-4-methylpentanl-1-ol (e)
  • Compound d (80.0 g, 255 mmol, 1.0 eq, 84% w/w) was added dropwise to a suspension of LAH (13.8 g, 363 mmol, 1.43 eq) in THF (500 mL) at 0° C. over 30 min and then stirred at room temperature for 1.5 hrs. The reaction was successively quenched by H2O (13.8 g), aqueous NaOH (13.8 mL, 15%) and H2O (41.4 g), then filtered via celite and concentrated. The residue was pruified by column chromatography on silica gel (PE/EtOAc=50/1-20/1) to give compound e (41.4 g, 73%) as a colorless oil.
  • 1H NMR (300 MHz, CDCl3): δ 0.73 (d, j=6.6 Hz, 3H), 1.03 (d, J=6.6 Hz, 3H), 1.27-1.65 (m, 1H), 1.87-1.96 (m, 2H), 2.10-2.17 (m, 1H), 2.29 (s, 3H), 2.86-2.93(m, 1H), 3.21-3.24 (m, 1H), 3.26-3.50 (m, 1H), 3.80 (s, 3H), 6.78 (d, J=8.1 Hz, 1H), 6.93 (s, 1H), 6.97 (d, J=8.1 Hz, 1H).
    • 5) Synthesis of 3-(2-methyloxy-5-methylphenyl)-4-methypentyl methylsulfonate (f)
  • MsCl (42.6 g, 558 mmol, 2.0 eq) was added in drops to a solution of compound e (41.4 g, 186 mmol, 1.0 eq) and TEA (56.5 g, 558 mmol, 3.0 eq) in DCM (750 mL) at 0° C. and the solution was stirred for 2 hrs at room temperature. After 2 hrs, the mixture was washed with H2O and then aqueous NaCl, dried over Na2SO4, filtered, and evaporated to give compound f (55.8 g, 100%) as a brown oil.
  • 1H NMR (400 MHz, CDCl3): δ 0.72 (d, J=6.4 Hz, 3H), 0.97 (d, J=6.4 Hz, 3H), 1.84-1.91 (m, 1H), 1.97-2.06 (m, 1H), 2.18-2.26 (m, 4H), 2.83-3.14 (m, 4H), 3.75 (s, 3H), 3.88-3.94 (m, 1H), 4.00-4.05 (m, 1H), 6.74 (d, J=8.4 Hz, 1H), 6.86 (s, 1H), 6.96 (d, J=8.4 Hz, 1H).
    • 6) Synthesis of 4-(2-methyloxy-5-methylphenyl)-5-methylhexanenitrile (g)
  • A mixture of compound f (55.8 g, 186 mmol, 1.0 eq) and NaCN (18.2 g, 372 mmol, 2.0 eq) in DMF (300 mL) was stirred at 75° C. overnight and distributed into EtOAc and H2O. The organic layer was washed with H2O and saturated aqueous NaCl, dried over Na2SO4, filtered, and evaporated to give compound g (38.5 g, 90%) as a colorless oil.
  • 1H NMR (400 MHz, CDCl3): δ 0.71 (d, J=6.8 Hz, 3H), 0.99 (d, J=6.8 Hz, 3H), 1.85-2.17 (m, 5H), 2.28 (s, 3H), 2.75-2.81 (m, 1H), 3.76 (s, 3H), 6.75 (d, J=8.4 Hz, 1H), 6.84 (s, 1H), 6.98 (d, J=8.4 Hz, 1H).
    • 7) Synthesis of 4-(2-methyloxy-5-methylphenyl)-5-methylhexanamide (h)
  • H2O2 (32.0 g, 282 mmol, 1.5 eq, 30% in H2O) was added dropwise to a suspension of compound g (43.5 , 188 mol, 1.0 eq) and K2CO3 (10.4 g, 75.2 mmol, 0.4 eq) in DMSO (220 mL) at room temperature, the solution was then stirred at room temperature for 3 hrs. Additional H2O2 (32.0 g, 282 mmol, 1.5 eq, 30% in H2O) was added dropwise at room temperature for 1 hr. The mixture was separated between EtOAc and H2O, the organic layer was washed with H2O and then saturated aqueous NaCl, dried over Na2SO4, filtered, and evaporated to give compound h (46.9 g, 100%) as a white solid.
  • 1H NMR (300 MHz, CDCl2): δ 0.72 (d, J=6.6 Hz, 3H), 1.00 (d, J=6.6 Hz, 3H), 1.73-2.21 (m, 5H), 2.28 (s, 3H), 2.79-2.84 (m, 1H), 3.79 (s, 3H), 5.38 (brs, 2H), 6.76 (d, J=8.4 Hz, 1H), 6.85 (s, 1H), 6.97 (d, J=8.4 Hz, 1H).
    • 8) Synthesis of 4-(2-methyloxy-5-methylphenyl)-5-methylhexanoic acid (i)
  • A mixture of compound h (46.9 g, 188 mmol, 1.0 eq), NaOH (30.1 g, 752 mmol, 4.0 eq) and H2o )100 mL) in EtOH (400 mL) was refluxed overnight and concentrated. pH of the residue was adjusted with 1N HCl to 2, the residue was then extracted with EtOAc. The organic layer was washed with aqueous NaCl, dried over Na2SO4, filtered, and evaporated to give compound i (47.1 g, 100%) as a brown oil.
  • 1NMR (300 MHz, CDCl3): δ 0.74 (d, J=6.6 Hz, 3H), 1.01 (d, J=6.6=Hz, 3H), 1.78-1.94 (m, 2H), 2.04-2.20 (m, 3H), 2.28 (s, 3H), 2.76-2.82 (m, 1H), 3.76 (s, 3H), 6.76 (d, J=8.4 Hz, 1H), 6.89 (s, 1H), 6.97 (d, J=8.4 Hz, 1H).
    • 9) Synthesis of (R)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid (1) and (S)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid (4)
  • HBr (235 mL, 33% in AcOH) solution was added to a solution of compound i (47.1 g, 188 mmol) in AcOH (235 mL) dropwise at room temperature, then refluxed overnight. The mixture was diluted with EtOAc and H2O. The organic layer was washed with H2O and saturated aqueous NaCl, and subsequently concentrated. The residue was diluted with EtOH (400 ml) and H2O (40 mL) with LiOH.H2O (31.6 g, 752 mmol) added; the mixture was stirred for 1.5 hours at room temperature and then concentrated. The residue was diluted, and acidified with 1N HCl to pH 2˜3. The organic layer was washed by H2O, and then aqueous NaCl, dried over Na2SO4, filtered, and evaporated. The residue was purified by column chromatography on silica gel (PE/EtOAc=100/1 to 10/1) to give compound 5 (22.2 g, 50%) as a white solid. 11.0 g of 5 was separated by chiral Prep-HPLC to give 4.5 g of compound 1 and 3.8 g of compound 4.
  • Compound 1: 1H NMR 9400 MHz, DMSO-d6): δ 0.68 (d, J=6.4 Hz, 3H), 0.92 (d, J=6.4 Hz, 3H), 1.68-1.97 (m, 5H), 2.17 (s, 3H), 2.65-2.68 (m, 1H), 6.66 (d, J=7.6 Hz, 1H), 6.76-6.79 (m, 2H), 8.83 (s, 1H), 11.84 (s, 1H); 1H NMR (600 MHz, CDCl3, δTMS=0.00 ppm): δ 6.66 (d, J=8.52 Hz, 2H), 6.85 (d, J=8.52 Hz, 2H), 1.85 (m, 1H), 2.67 (m, 1H(, 1.80, 2.17 (m, 2H), 2.18, 2.11 (m, 2H), 1.85 (m, 1H), 1.01 (d, J=6.58 Hz, 3H), 0.74 (d, J=6.65 Hz, 3H), 2.27 (s, 3H); LCMS [mobile phase: from 95% water (0.01% NH4Ac) and 5% CH3CN to 5% water (0.01% NH4Ac) and 95% CH3CN in 6 min, finally under these conditions for 0.5 min] purity is >95%, Rt=3.847 min; MS Calcd.: 236; MS Found: 237 ([M+H]+); Chiral HPLC (Chiralcel OJ-H column): Rt=7.16 min (Hex/t-Bu-tOH/TFA=95:5:0.3), ee=100%; [α]D 25=−19.4 (c 0.72, CH2Cl2).
  • Compound 4: 1H NMR (400 MHz, DMSO-d6): δ 0.68 (d, J=6.4 Hz, 3H), 0.92 (d, J=6.4 Hz, 3H), 1.66-2.01 (m, 5H), 2.17 (s, 3H), 2.65-2.67 (m, 1H), 6.66 (d, J=8.4 Hz, 1H), 6.76-6.79 (m, 2H), 8.79-8.84 (brs, 1H), 11.79-11.86 (brs, 1H); 1H NMR (600 MHz, CDCl3, δTMS=0.00 ppm): δ 6.65 (d, J=8.5 Hz, 2H), 6.84 (d, J=8.5 Hz, 2H), 6.84 (1H, s, H-5), 2.67 (m, 1H), 1.81, 2.18 (m, 2H), 2.20, 2.13 (m, 2H), 1.86 (m, 1H), 1.02 (d, J=6.5 Hz, 3H), 0.74 (d, J=6.5 Hz, 3H), 2.24 (s, 3H); LCMS [mobile phase: from 95% water (0.01% NH4Ac) and 5% CH3CN to 5% water (0.01% NH4Ac) and 95% CH3CN in 6min, finally under these conditions for 0.5 min.] purity is >95%, Rt=3.849 min; MS Calcd.: 236; MS Found: 237 ([M+H]+); Chiral HPLC (Chiralcel OJ-H column): rt=10.24 min (Hex/t-ButOH/TFA=95:5:0.3; enantiomer: Rt=7.31 min), ee=98%; [α]D 25=+20.0 (c 0.72, CH2Cl2)
  • Compound 5: 1H NMR spectrum (600 MHz, CDCl3, δTMS=0.00 ppm): δ 6.65 (d, J=8.5 Hz, 2H), 6.85 (d, J=8.5 Hz, 2H), 6.85 (s, 1H), 2.66 (m, 1H), 1.82, 2.18 (m, 2H), 2.20, 2.13 (m, 2H), 1.87 (m, 1H), 1.02 (d, J=6.5 Hz, 3H), 0.74 (d, J=6.5 Hz, 3H), 2.24 (s, 3H).
    • Example 5 Study on the Effects in Protection Against MPP+ Induced CGNs Damage
  • N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is the precursor of 1-methyl-4-phenylpyridinium (MPP+), a mitochondrial electron-transport chain (ETC) complex I inhibitor generated from MPTP by the dopaminergic catabolic enzyme monoamine oxidase B. Accumulation of MPP+ in dopaminergic neurons results in ATP deficiency, collapse of the mitochondrial membrane potential, opening of the mitochondrial permeability transition pore (mPTP), and production of ROS, leading to apoptosis. MPTP/MPP+ has been widely used in in vitro and in vivo neuronal damage to model dopaminergic neurodegeneration characteristic of Parkinson's disease.
  • Primary cerebellar granule neurons (CGNs) were prepared from 8 days old Sprague-Dawley rats, as described in a previous publication (Du, Bales et al. 1997). CGNs cultured in vitro for 7 days were pre-treated with serial concentrations of compounds 1-5 from 6 μM to 50 μM respectively for 2 hours, vehicle group was incubated with 0.1% DMSO. The cells were then exposed to 150 μM MPP+ for 36 hours. For assessment of the cell viability, 15 μl of 5 mg/ml MTT solution was added to each well containing cell in 100 μl of medium, and the plates were incubated for 4 hours in a humidified incubator at 37° C. After incubation, 100 μl of absolute DMSO was added and incubated for 10 min. Absorbance at 570 nm of each well was measured with a microplate reader.
  • FIG. 1 shows that compounds 1-5 prevented MPP+-induced CGNs damage. Compound 1 shows neuroprotective effect on MPP+-induced primary SD rat CGNs damage in a dose-dependent manner with Emax at the concentration of 50 μM. Compound 2 has neuroprotective effect on MPP+-induced primary SD rat CGNs damage with Emax at the concentration of 50 μM. Compound 3 has neuroprotective effect on MPP+-induced primary SD rat CGNs damage with Emax at the concentration of 25 μM. Compound 4 has neuroprotective effect on MPP+-induced primary SD rat CGNs damage with Emax at the concentration of 12 μM. Compound 5 has neuroprotective effect on MPP+-induced primary SD rat CGNs damage in a dose-dependent manner with Emax at the concentration of 50 μM.
  • As presented in FIG. 1, cell viability of CGNs has been significantly increased upon pretreating with different concentrations of compounds 1-5. Thus, FIG. 1 shows that compounds 1-5 can protect against neural damage induced by MPP+, and be used to treat neurodegenerative diseases.
    • Example 6 Study on the Effects in Protecting PC12 Cells Against 6-OHDA-Induced Neuronal Damage
  • Rat pheochromocytoma cells (PC12) cells were seeded in c 100 cm dishes at a density of 1.5˜2×106 cells/dish. After culturing in a medium with a low serum level (F-12K medium with 0.5% FBS) for 24 hours, the cells were pretreated with serial concentrations of compound 1 from 6 μM to 50 μM for 12 hours. The cells were then exposed to 1 mM 6-OHDA for 2 hours. Cell viability of cells were assessed similarly as described in Example 5. As shown in FIG. 2A, PC12 cells pretreated with compound 1 did not exhibit any cytotoxicity at all tested concentrations. 6-OHDA was cytotoxic to PC12 cells but compound 1 could alleviate the cytotoxic effect in a dose-dependent manner as shown in FIG. 2B. Compound 1 exhibited a significant and maximum neuroprotective effect to 6-OHDA treated PC12 at 50 μM. Baicalein, one of the main flavonoids extracted from the root of Scutellaria baicalensis Georgi (SBG), has been demonstrated to prevent against neuronal damage induced by 6-OHDA or MPTP in both in vitro and in vivo models of Parkinson's disease (Im, Joo et al. 2005; Lee, Noh et al. 2005; Cheng, He et al. 2008; Mu, He et al. 2009; Mu, He et al. 2011). Here baicalein was used as a positive control, which at the concentration of 100 μM obviously protected PC12 cells against 6-OHDA-induced neuronal damage.
  • Thus, FIGS. 2A and 2B show that compound 1 can have neroprotective effect to 6-OHDA treated PC12. Further, compound 1 has neuroprotective effect on 6-OHDA-induced PC12 cell damage in a dose-dependent manner with maximum efficacy (Emax)at the concentration of 50 μM.
    • Example 7 Study of the Effect in Attenuating MPTP-Induced DA Neuron Injury
  • Zebrafish embryo was dechorinated at 1 day post fertilization (dpf) and was cultured under co-treatment of 200 μM MPTP and various concentrations of compound 1 for 48 hours. Afterwards, zebrafish was fixed in 4% paraformaldehyde in PBS for 5 hours, rinsed and stored at −20° C. in 100% EtOH. Whole-mount immunostaining was done by standard methods (Bitzur, Kam et al. 1994). Compound 1 attenuated MPTP-induced DA neuron injury in a dose-dependent manner as shown in FIGS. 3D-F. Further, compound 1 can protect MPTP-induced dopaminergic neuron loss in zebrafish in a dose-dependent manner with E. at the concentration of 5 μM as shown in FIG. 3G in which the results were expressed quantitatively as percentages of area of TH-positive cells in comparison to untreated control group. Thus FIG. 3G shows that compound 1 can protect against TH-positive cells loss.
    • Example 8 Study on the Effect in Attenuating MPTP-Induced Reduction of Total Travelling Distance for Zebrafish Larvae
  • The 3 dpf zebrafish larvae were co-treated with 200 μM MPTP and various concentrations of compound 1 for 4 days. At 7 dpf, the total distance the larvae traveled was recorded using a 96-well plate (with 1 fish/well and 12 larvae per group) filled with 200 μl embryo medium. Larvae were allowed to accommodate in the system for an hour before data acquisition. The swimming pattern of each larva was recorded for 10 min in 3 times, with each record session separated by 10 min. The total distance traveled was estimated as the distance (in mm) that the larva had moved during one session (10 min). As shown in FIGS. 4A and 4B, compound 1 attenuated MPTP-induced reduction of total distance traveled of the larvae in a dose dependent manner.
    • Example 9 Study on Synergistic Neuroprotective Effect of Compound 1 and Chrysin
  • Primary cerebellar granule neurons (CGNs) were prepared from 8 days old Sprague-Dawley rats as described (Zhang et al., 2012). CGNs that have been cultured in vitro for 7 days were pre-treated with serial concentrations of compound 1 from 3 μg/ml to 50 μg/ml for 2 hours or with 0.1% DMSO (vehicle group). The cell viability was estimated similarly as in Example 5.
  • As shown in FIG. 5, both compound 1 and chrysin protected MPP+-induced cell damage in CGNs in a dose-dependent manner. The cell viability was significantly enhanced when the cells were treated with 25 and 50 μM of compound 1 as well as with 12 and 25 μM of chrysin as compared with the control group treated with MPP+ alone (p<0.05). CGNs were also co-treated with compound 1 and chrysin to explore the pharmacological interaction between two compounds. It is found that at higher concentrations such as 25 and 50 μM, the co-treatment did not exert any neuro-protective effect but imposed toxicity on the CGNs (data not shown). Conversely, at lower concentrations of 3 and 6 μM, compound 1 and chrysin showed significant synergistic neuroprotective effect as compared with cells treated with MPP+ alone, MPP+/compound 1 and MPP+/chrysin.
    • Example 10 Study of Neuroprotective Effect of Compound 1 in MPTP-Injected Mice Animals and Drug Treatment
  • Adult male C57BL/6J mice (8-10 weeks of age, 18-22 g) were used in this study. The animals were maintained in 12/12 h light/dark cycle and allowed access to food and water ad libitum. They were allowed to acclimate for 7 days before treatment. As shown in FIG. 6, all the animals were conducted behavioral training (pole climbing, rotarod running and foot printing) for total 4 days before MPTP injection. Then the mice were injected intraperitioneally (i.p.) with 20 mg/kg MPTP hydrochloride (Sigma Aldrich, St. Louis, Mo.), at 2 h internal for total 4 injections. Normal control group were received saline (0.1 mL/10 g) by i.p. One hour prior each MPTP injection, compound 1 (5, 10 and 20 mg/kg), rasagiline (1 mg/kg) and equal volume of vehicle (olive oil, 0.1 mL/10 g) were administrated by i.g. Then, compound 1, rasagiline or vehicle was given by i.g. once per day for total 7 days (day 1-7). Each of six groups was comprised of 10 mice.
    • Behavioral Testing
  • twenty-four hours after administration of the last dose of drugs (on the day 8 as shown in FIG. 6), mice were observed for neurobehavoral changes by pole test, rotarod test and footprint test. All the tests were done between 9 am and 2 pm under normal animal room lighting.
  • The pole test was performed to detect impairment of limb movement. A table tennis ball (5 cm diameter) was equipped on the top of a vertical pole (55 cm length and 1 cm diameter). The pole was wrapped with a double layer of gauze to avoid slipping. The animal was placed head upward on the table tennis ball. The time the animal took to climb down to the floor was used to indicate performance. Three-time repeated testes were carried out for each animal and the mean values were used for statistical analysis.
  • The rotarod test could reveal motor coordination ability. A Rotarod system (YLS-4C, Academy of Medical Sciences of Shandong Province, China) was set at an accelerating program with a starting speed of 5 rpm to a final speed of 40 rpm. Mice were allowed to adjust their posture in order to maintain their balance on a rotating rod during speed accelerating. Infrared beams are used to detect with a mouse has fallen onto the base grid beneath the rotarod. The system logs the fall as the end of the experiment for that mouse, and the total time on the rotarod was recorded. For testing, 5 mice were tested at the same time. The average retention time on the rod was calculated.
  • In the footprint test, mice with their forepaws and hind paws colored with red ink were trained to walk through a 5 cm-wide, 100-cm-long corridor. Their footsteps were recorded on a white absorbing paper.
    • Tissue Preparation
  • Mice were sacrificed for tissue preparation on the day 9 as described in FIG. 6. Mice in each group were anesthetized and perfused intracardially with 0.9% sodium chloride containing heparin, and then fixed with 4% paraformaldehyde (PFA). Each brain was removed, dehydrated with graded alcohol and embedded in paraffin wax, coronally sectioned for 5 μM. The rostral and caudal part of the brain was divided for immunohistochemistry of substantia nigra pars compacta (SNpc).
  • Anti-Tyrosine Hydroxylase (TH) Immunohistochemistry
  • The immunohistochemistry was conducted as previously described (Lee, Kim et al. 2011; Levites, Weinreb et al, 2001). Briefly, sections were deparaffinized in xylene and rehydrated in a graded ethanol series. Sections were incubated with 3% hydrogen peroxide (H2O2) for 10 min at room temperature to inactive endogenous peroxidase activity followed by antigen retrieval in citrate buffer for 15 min in a microwave oven at 95° C. Non-specific protein binding was blocked with 10% bovine serum in PBS (0.01 M, pH 7.4). Between each treatment, the slides were washed at least three times with deionized water for 5 min. Sections were then incubated for 1 h at room temperature with a rabbit anti-mouse TH polycolonal antibody (1:1000; Millipore, USA) diluted in Immunol Staining Primary Antibody Dilution Buffer. Then the sections were incubated with a biotinylated HRP-conjugated secondary antibody for 30 min at room temperature. TH-positive neurons were then visualized using a DAB Kit according to the manufacturer's instructions (Shanghai, Gene Company, China). The peroxidase reaction was stopped after 3 min Finally, sections were cover slipped with neutral balsam. The results were analyzed by counting the numbers of TH-positive cells at ×10 magnifications on a stereomicroscope (BX51, Olympus Corp. Japan). TH-positive cells in 8 position-matched sections of each mouse were counted manually by operator who was blinded to the drug treatment. The average number of TH-positive cells per section was used to represent dopaminergic neuron livability.
    • Results
  • Compound 1 Ameliorated the Movement Impairments of MPTP-Treated Mice
  • Loss of SNpc DA neurons contributes to the movement abnormalities observed in PD. The movement of mice following MPTP injections was assessed. FIGS. 7A to 7D showed that MPTP significantly increased the time climbing down from the pole (FIG. 7A), delayed the time of crossing the corridor (FIG. 7B), reduced the time of mice on rotating rotor rod (FIG. 7C) and caused mice to lose their normal gait, shortening stride length (FIG. 7D). As such, FIGS. 7A to 7D show that compound 1 treatment largely corrected the movement abnormalities in a dose-dependent manner.
    • Effect of Compound 1 on SNpc DA Neurons Loss of MPTP-Treated Mice
  • Injection of MPTP (20 mg/kg) every 2 h for a total of four doses over an 8 h period in 1 d caused about 40% TH-positive DA neurons loss in the SNpc at 7 days post injection, and the loss of TH-positive cells appeared somewhat more marked in the middle than in the rostral and the caudal part (FIGS. 8A and B). Pre- and post-treatment with compound 1 significantly reduced the MPTP-induced TH-positive cell body loss in a dose-dependent manner (FIGS. 8A and 8C). The same schedule was used for rasagiline, a selective MAO-B inhibitor approved for treatment of PD patients, also prevented against the MPTP-induced TH-positive cell body loss.
    • CONCLUSION
  • The present invention provides three isolated and purified compounds: 1 ((R)-4-(2-hydroxy-5-methylphenyl)-5-mehtylhexanoic acid), 2 ((4S)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid) and 3 ((4R)-4-(3-hydroxy-3-methyl-6-oxocyclohex-1-enyl)-5-methylhexanoic acid), isolated form A. oxyphyllae fructus, with neuroprotective effect as shown in the above examples; and two synthesized compounds: 4 ((S)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) and 5 (4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid) with neuroprotective effect. These five lead compounds have neuroprotective effects which could be developed into therapeutic agent for neurodegenerative diseases (e.g. Parkinson's disease). Further, the present invention provides a simple and easy method for extraction and purification of these three novel compounds 1-3 from A. oxyphyllae fructus and an elaborated procedure for synthesizing compounds 1, 4 and 5. In vitro neuroprotective activity on CGNs of compounds 1-5 is also presented. Furthermore, this invention shows that compound 1 possesses in vivo and in vitro neuroprotective activities on PC12 cells and zebrafish.
  • Data presented herein show that, on MPP+ induced primary cultured cerebral granular neurons (CGNs) damage, compounds 1-5 showed concentration dependent neuroprotective effect at concentration of 6-50 μM. Moreover, compound 1 could prevent PC12 cells against 6-OHDA-induced neurtoxicity; protect zebrafish from MPTP-induced dopaminergic neuron loss; and improve the impairment of swimming behavior induced by MPTP in zebrafish. Compound 1 could also ameliorate the movement impairments of MPTP-treated mice and reduced the MPTP-induced TH-positive cell body loss. In addition, compound 1 and chrysin (another known flavonoid compound isolated from A. oxyphyllae fructus) showed synergistic neuroprotective effects on MPP+-induced CGNs damage. These results suggest that compounds 1-5 alone or their combination with other neuroactive compounds can be used as a drug for treating neurodegenerative diseases such as Parkinson's disease.
  • In addition to the single compound method of treatment described above, the combination of compound 1 and chrysin show synergistic effect. One skilled in the art in the course of developing a treatment regime will be able to determine the optimal therapeutic dose to administer to a patient either using one of the above compounds or in combination without undue experimentation.
  • The exemplary embodiments of the present invention are thus fully described. Although the description referred to particular embodiments, it will be clear to one skilled in the art that the present invention may be practiced with variation of these specific details. Hence this invention should not be construed as limited to the embodiments set forth herein.
  • Unless define otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are now described. All publication mentioned herein are incorporated herein by reference to described and disclose specific information for which the reference was cited in connection with.
  • All references cited above and in the following description are incorporated by reference herein. The practice of the invention is exemplified in the following non-limiting examples. The scope of the invention is defined solely by the appended claims, which are in no way limited by the content or scope of the examples.
    • REFERENCES
  • An, L., S. Guan, et al. (2006). “Protocatechuic acid from Alpinia oxyphylla against MPP+-induced neurotoxicity in PC12 cells.” Food and chemical toxicology 44(3): 436-443.
  • Bitzur, S., Z. Kam, et al. (1994). “Structure and distribution of N-cadherin in developing zebrafish embryos: morphogenetic effects of ectopic over-expression.” Dev Dyn 201(2): 121-136.
  • Cheng, Y., G. He, et al. (2008). “Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile.” Neurosci Lett 44(1): 16-20.
  • Du, Y., K. R. Bales, et al. (1997). “Activation of a caspase 3-related cysteine protease is required for glutamate-mediated apoptosis of cultured cerebellar granule neurons.” Proceedings of the National Academy of Sciences 94(21): 11657-11662.
  • Graziose, R., M. A. Lila, et al. (2010). “Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional foods.” Curr Drug Discov Technol 7(1): 2-12.
  • Im, H. I., W. S. Joo, et al. (2005). “Baicalein prevents 6-hydroxtdopamine-induced dopaminergic dysfunction and lipid peroxidation in mice.” J Pharmacol Sci 98(2): 185-189.
  • Lee, D. H., C. S. Kim, et al. (2011) Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro. Food Chem Toxicol 49(1):271-280.
  • Lee, H. J., Y. H. Noh, et al. (2005). “Baicalein attenuates 6-hyroxydopamine-induced neurotoxicity in SH-SY5Y cells.” Eur J Cell Biol 84(11): 897-905.
  • Levites Y., O. Weinreb, et al. (2001) Green tea polyphenol (−)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78(5):1073-1082.
  • Li, W., M. Mak, et al. (2009). “Novel anti-Alzheimer's dimer Bis(7)-cognitin: cellular and molecular mechanisms of neuroprotection through multiple targets.” Neurotherapeutics 6(1): 187-201.
  • Lin, M. T. and M. F. Beal (2006). “Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.” Nature 44(7113): 787-795.
  • Mandel, S., T. Amit, et al. (2007). “Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents.” Prog Neurobiol 82(6): 348-360.
  • Mu, X., G. He, et al. (2009). “Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro.” Pharmacol Biochem Behav 92(4): 642-648.
  • Mu, X., G. R. He, et al. (2001). “Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice.” Pharmacol Biochem Behav 98(2): 286-291.
  • Yang, M., J. Sun, et al. (2009). “Phytochemical analysis of traditional Chinese medicine using liquid chromatography coupled with mass spectrometry.” Journal of Chromatography A 1216(11): 20452062.
  • Zhang, X., G. F. Shi, et al. (2011). “Anti-ageing effects of protocatechuic acid from Aplinia on spleen and liver antioxidative system of senescent mice.” Cell Biochemistry and Function 29(4): 342-347.
  • Zhang, Z. J., L. C. V. Cheang, et al. (2012). “Ethanolic Extract of Fructus Aplinia oxyphylla Protects Against 6-Hydroxydopamine-Induced Damage of PC12 Cells In Vitro and Dopaminergic Neurons in Zebrafish.” Cellular and molecular neurobiology 32(1): 27-40.

Claims (8)

1. A compound with Formula I:
Figure US20160376216A1-20161229-C00013
wherein R1 and R3 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, alkenly, alkynyl, aryl, heteroaryl, carboxy, alkyloxy, hydroxyl, amino, nitro, alkylthio, acyl, cyano, acylamino, halo and ester; and
R2 and R4 are independently selected from the group consisting of H, unsubstituted or substituted alkyl, cycloalkyl, aryl, heteroaryl, alkyoxy, acyl, acylamino and halo.
2. The compound of claim 1, wherein R1 and R3 are independently unsubstituted or substituted (C1-C3) alkyl; and R2 and R4 are H.
3. The compound of claim 1, wherein said compound is an isolated and purified ((R)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid).
4. The compound of claim 1, wherein said compound is hydroxy-5-methylphenyl)-5-methylhexanoic acid) or (4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid).
5.-8. (canceled)
9. A method of treating Parkinson's disease, or protecting against neural damage or neural cells loss, comprising the step of administering said compound of claim 1 to a subject in need.
10. A method of treating neurodegenerative disease in a human patient comprising administrating to the patient a therapeutically effective amount of said compound of claim 1 and chrysin, wherein said compound exhibits a synergistic effect with said chrysin for neuroprotective effect.
11.-31. (canceled)
US15/260,336 2013-03-14 2016-09-09 Novel anti-neurodegenerative natural compounds isolated from Alpiniae Oxyphyllae Fructus and their total synthesis Abandoned US20160376216A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/260,336 US20160376216A1 (en) 2013-03-14 2016-09-09 Novel anti-neurodegenerative natural compounds isolated from Alpiniae Oxyphyllae Fructus and their total synthesis
US15/727,638 US10011555B2 (en) 2013-03-14 2017-10-09 Methods of treating Parkinson's disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782870P 2013-03-14 2013-03-14
US14/210,467 US9475749B2 (en) 2013-03-14 2014-03-14 Anti-neurodegenerative natural compound isolated from alpiniae oxyphyllae fructose and their total synthesis
US15/260,336 US20160376216A1 (en) 2013-03-14 2016-09-09 Novel anti-neurodegenerative natural compounds isolated from Alpiniae Oxyphyllae Fructus and their total synthesis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/210,467 Continuation US9475749B2 (en) 2013-03-14 2014-03-14 Anti-neurodegenerative natural compound isolated from alpiniae oxyphyllae fructose and their total synthesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/727,638 Continuation US10011555B2 (en) 2013-03-14 2017-10-09 Methods of treating Parkinson's disease

Publications (1)

Publication Number Publication Date
US20160376216A1 true US20160376216A1 (en) 2016-12-29

Family

ID=51530010

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/210,467 Active US9475749B2 (en) 2013-03-14 2014-03-14 Anti-neurodegenerative natural compound isolated from alpiniae oxyphyllae fructose and their total synthesis
US15/260,336 Abandoned US20160376216A1 (en) 2013-03-14 2016-09-09 Novel anti-neurodegenerative natural compounds isolated from Alpiniae Oxyphyllae Fructus and their total synthesis
US15/727,638 Active US10011555B2 (en) 2013-03-14 2017-10-09 Methods of treating Parkinson's disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/210,467 Active US9475749B2 (en) 2013-03-14 2014-03-14 Anti-neurodegenerative natural compound isolated from alpiniae oxyphyllae fructose and their total synthesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/727,638 Active US10011555B2 (en) 2013-03-14 2017-10-09 Methods of treating Parkinson's disease

Country Status (7)

Country Link
US (3) US9475749B2 (en)
EP (1) EP2970090B1 (en)
JP (1) JP6422452B2 (en)
CN (1) CN105431405B (en)
CA (1) CA2905622A1 (en)
ES (1) ES2736599T3 (en)
WO (1) WO2014141169A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2905622A1 (en) * 2013-03-14 2014-09-18 University Of Macau Novel anti-neurodegenerative natural compounds isolated from alpiniae oxyphyllae fructus and their total synthesis
CN107382698A (en) * 2016-05-14 2017-11-24 深圳瀜新生物科技有限公司 A kind of preparation method of the compound as neuroprotective agent
CN109748786A (en) * 2018-12-30 2019-05-14 深圳瀜新生物科技有限公司 A kind of synthetic method of the compound as neuroprotective agent
CN111505138B (en) * 2020-04-24 2022-07-05 广东一方制药有限公司 Characteristic spectrum construction method and quality detection method of fructus alpiniae oxyphyllae formula granules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275236A1 (en) * 2013-03-14 2014-09-18 University Of Macau Novel anti-neurodegenerative natural compounds isolated from Alpiniae Oxyphyllae Fructus and their total synthesis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2720542A (en) * 1954-08-24 1955-10-11 Merck & Co Inc 1-hydroxy-4-methoxy-7-keto-13-methyl-5, 6, 7, 9, 10, 13-hexahydrophenanthrene and processes of preparing the same
GB1265800A (en) * 1968-11-05 1972-03-08
US4022791A (en) * 1975-06-03 1977-05-10 Pfizer Inc. 2-Aminomethyl-3,4-dihydronaphthalenes
JPH03261759A (en) * 1990-03-09 1991-11-21 Meiji Seika Kaisha Ltd Nanaomycin a intermediate and synthesis thereof
US5273999A (en) * 1991-09-10 1993-12-28 Hoffmann-La Roche Inc. Carboxylic acid leukotriene B4 antagonists
US6376546B1 (en) * 1997-10-14 2002-04-23 Asahi Kasei Kabushiki Kaisha Biphenyl-5-alkanoic acid derivatives and use thereof
US6307107B1 (en) * 1999-09-20 2001-10-23 E.I. Du Pont De Nemours And Company Hydroformylation of acyclic monoethylenically unsaturated compounds to corresponding terminal aldehydes
JP2009530399A (en) * 2006-03-22 2009-08-27 シンデクサ ファーマシューティカルズ コーポレーション Compounds and methods for the treatment of diseases associated with ER stress
EP2086318A4 (en) * 2006-10-10 2009-12-23 Burnham Inst Medical Research Neuroprotective compositions and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140275236A1 (en) * 2013-03-14 2014-09-18 University Of Macau Novel anti-neurodegenerative natural compounds isolated from Alpiniae Oxyphyllae Fructus and their total synthesis

Also Published As

Publication number Publication date
JP2016511282A (en) 2016-04-14
CN105431405B (en) 2018-06-01
US10011555B2 (en) 2018-07-03
US9475749B2 (en) 2016-10-25
JP6422452B2 (en) 2018-11-14
CA2905622A1 (en) 2014-09-18
US20180065912A1 (en) 2018-03-08
EP2970090B1 (en) 2019-05-08
WO2014141169A2 (en) 2014-09-18
EP2970090A2 (en) 2016-01-20
WO2014141169A3 (en) 2015-04-09
CN105431405A (en) 2016-03-23
ES2736599T3 (en) 2020-01-03
EP2970090A4 (en) 2016-11-23
US20140275236A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
US11660305B2 (en) Tryptamine compositions for enhancing neurite outgrowth
US11896587B2 (en) Tryptamine compositions for enhancing neurite outgrowth
US10011555B2 (en) Methods of treating Parkinson&#39;s disease
Saha et al. Evaluation of antinociceptive and anti-inflammatory activities of extract and fractions of Eugenia jambolana root bark and isolation of phytoconstituents
KR20010071822A (en) Hypericin and Hypericum Extract : Specific T-type Calcium Channel Blocker, and Their Use as T-type Calcium Channel Targeted Therapeutics
JP2005526053A (en) Isolation, purification, and structural identification of bioactive components of water-soluble extracts of plant species to promote the process of warm-blooded animal immunity, anti-inflammatory, anti-tumor, and DNA repair
KR101395342B1 (en) COMPOSITION MADE OF THE COMPOUNDS EXTRACTED FROM Morus alba FOR PREVENTION AND TREATMENT OF CEREBROPATHIA
US11643428B2 (en) Therapeutic drug for neurodegenerative disease and application thereof
CA2909280C (en) Chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders
Yoon et al. Neuroprotective lignans from Biota orientalis leaves
KR100588477B1 (en) Pharmaceutical composition for degenerative central nervous system disease prevention
JP2008044940A (en) Novel compound separated from fruiting body of antrodiacamphorata, and pharmaceutical composition prepared therefrom
KR20080037854A (en) A composition for preventing or treating obesity or type 2 diabetes
WO2013179309A1 (en) Novel compounds as memory enhancers

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION